Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO TAT 2022 | BDTX-1535: A novel treatment for EGFR-mutated NSCLC and glioblastoma

Matthew Lucas, PhD, Black Diamond Therapeutics, Cambridge, MA, talks on BDTX-1535, an inhibitor of selected EGFR mutations in non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). BDTX-1535 is designed to be able to penetrate the brain, aiming to treat GBM as well as central nervous system (CNS) metastases in patients with NSCLC. The drug targets active dimers (the formation of which is promoted by intracellular domain mutations in NSCLC and extracellular domain mutations in GBM) over the inactive monomeric form of EGFR. BDTX-1535 is currently entering a Phase I trial (NCT05256290), recruiting biomarker-selected patients with recurrent EGFR-mutated GBM or with locally advanced/metastatic NSCLC who have EGFR mutations of intrinsic/acquired resistance. Patients must have previously progressed under standard-of-care, and were eligible either with or without CNS disease. The primary outcome is dose-limiting toxicity, and the trial aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.